Newsmaker – Bob Atwill

PERTH-BASED burns treatment-focused biomedical company Clinical Cell Culture Ltd has appointed Bob Atwill as chief executive. He replaces the company’s chief financial officer Andrew Cannon, who has been C3’s interim CEO, pending a permanent appointment. Mr Atwill and Mr Cannon will both take up positions on the company’s board. Mr Atwill, who will assume the position with immediate effect, will be based in Canberra and will split his time between C3’s operational headquarters in Cambridge, in the UK, and Australia. He is an experienced corporate executive with broad international experience in the pharmaceutical and medical services sectors, having worked in commercialising of medical devices in international markets. Mr Atwill was previously sales and marketing director of London Stock Exchange-listed Corin Group PLC, an orthopaedic products group, where he helped expand the business through organic growth, and strategic acquisitions. Mr Atwill has been in Australia since September 2005 and has consulted to biotech and biopharmaceutical companies on capital raisings and commercialisation strategies.

Add your comment

BNIQ sponsored byECU School of Business and Law


6th-Australian Institute of Management WA20,000
7th-Murdoch University16,584
8th-South Regional TAFE10,549
9th-Central Regional TAFE10,000
10th-The University of Notre Dame Australia6,708
47 tertiary education & training providers ranked by total number of students in WA

Number of Employees

BNiQ Disclaimer